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ABSTRACT
Background: Epinastine hydrochloride and fexofenadine hydrochloride , the second-generation antihista-
mines, are largely used in the indication of allergic rhinitis in Japan. The purpose of this study was to compare
the protective efficacy of epinastine hydrochloride or fexofenadine hydrochloride using a nasal provocation test
with Japanese cedar pollen allergen.
Methods: A single-dose, placebo-controlled, single-blind crossover clinical study was conducted in patients
with Japanese cedar pollinosis. The pollen exposure was done by the antigen provocation by disc method and
involved repeated provocation five times per day.
Results: Among the active agents studied―epinastine hydrochloride and fexofenadine hydrochloride―
epinastine hydrochloride significantly decreased the number of sneezing attacks and the quantity of nasal dis-
charge for 3 hours after drug administration compared with placebo, a finding supported by the quantity of na-
sal discharge in the nasal findings. In this study, fexofenadine hydrochloride showed no significant difference
compared with placebo.
Conclusions: This study demonstrates better protection with epinastine hydrochloride than with fexofenadine
hydrochloride or placebo in a nasal provocation test with Japanese cedar pollen allergen.
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INTRODUCTION
Pollinosis is seasonal allergic rhinitis due to pollen
antigens, and its prevalence is high enough to be
called a national disease in Japan. Among the many
pollen antigens, Japanese cedar pollinosis is the most
common.1 Government policies after World War II
led to the planting of Japanese cedar trees, and the
area planted with Japanese cedar trees began to in-
crease in the late 1960’s. In the early 1970’s, the num-
ber of patients increased rapidly, and currently 10―
20% of the Japanese population suffers from Japanese
cedar pollinosis, as has been reported in several stud-
ies.2
In the treatment of pollinosis , second-generation
antihistamines are used as initial therapy to inhibit
the hypersensitivity reaction caused by repeated anti-
gen exposure.3 The Practical Guideline for Manage-
ment of Allergic Rhinitis states that these agents are
the first-line agents of choice for the treatment after
onset of symptoms such as sneezing and rhinorrhea,
and thus are an essential component of pollinosis
therapy.4 Presently , several second-generation anti-
histamines are marketed with the allergic rhinitis in-
dication. To provide objective information concerning
drug selection, various studies to evaluate efficacy are
being conducted in the form of clinical studies in the
field,5 studies in environmental exposure units,6 anti-
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Table 1 Nasal finding score
gen provocation tests,7 and QOL surveys.8 The anti-
gen nasal provocation test is a test in which the anti-
gen is applied directly to the nasal mucosa to elicit na-
sal symptoms from such a stimulation.9 Since this is a
quantitative clinical study, where a fixed amount of
antigen is applied, it is possible to reproducibly elicit
the allergy reactions and allows the evaluation of
drugs for their treatment effect of nasal symptoms.
In this study, we examined patients with Japanese
cedar pollinosis using Japanese cedar antigen discs to
conduct the nasal provocation test and evaluated two
second-generation antihistamines, epinastine hydro-
chloride tablets and fexofenadine hydrochloride tab-
lets, for efficacy compared with placebo in a cross-
over clinical study.
METHODS
SUBJECTS
This study was conducted between August 14 and
October 2, 2004. The subjects were male and female
volunteers with Japanese cedar pollinosis who were
20 years old or older. The inclusion criteria required
that the subjects have a CAP-RAST score for Japa-
nese cedar of 2 or greater , show a positive nasal
provocation reaction to the Japanese cedar antigen
disc (more than two symptoms by the nasal provoca-
tion test from among nasal itching, sneezing, rhinor-
rhea and nasal congestion), and provide written con-
sent to participate in this study.10
The following subjects were excluded.
* Subjects with a history of hypersensitivity to the
components of the study drugs
* Subjects who were unable to stop smoking on the
days of the clinical study
* Subjects who had used steroids within one month
of the start day of the clinical study
* Subjects who within one week of the start day of
the clinical study used drugs that may affect the re-
sults of the clinical study (antihistamines, antiallergic
drugs, vasoconstrictors)
* Subjects undergoing desensitization therapy
* Subjects with nasal diseases that affect the assess-
ment of the nasal provocation reaction , such as
acutechronic rhinitis , nasal polyps , hypertrophic
rhinitis, deviated septum or sinusitis
* Subjects who were reactive to multiple antigens
including pollens other than Japanese cedar ( rag-
weed, mugwort), and had worsening of nasal symp-
toms when the nasal provocation test was conducted
during the season of dispersion of the pollen
STUDY DRUGS, STUDY DESIGN
Study drugs were epinastine hydrochloride 20 mg
tablets (epinastine) , fexofenadine hydrochloride 60
mg tablets (fexofenadine), and placebo indistinguish-
able from epinastine (provided by Nippon Boehringer
Ingelheim Co., Ltd., Hyogo, Japan with fees paid).
The clinical study consisted of four visits. Visit 1
consisted of screening tests, and visits 2, 3 and 4 in-
volved nasal provocation tests using Japanese cedar
antigen discs.
In the study design, the three study drugs were ad-
ministered to subjects as a single dose on the days of
the three nasal provocation tests in an open 3-way
crossover method in the order assigned by the ran-
domization (Fig. 1). A study drug administrator who
was neither the physician nor the clinical study col-
laborator conducted the randomization, and the study
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Fig. 2 Observed endpoints
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①: Observed endpoints at 5 minutes after antigen provocation
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Rhinoscope examination (swelling and color of the inferior turbinate
mucosa, quantity of water discharge)
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Anterior rhinoscope (VTR recording)
②: Blood sampling (histamine release rate measurements)
Table 2 Characteristics of subjects
5male
Sex
4female
23.56 ± 0.57mean ± S.E.Age (years) 
16.67 ± 1.16mean ± S.E.Age at onset (years) 
8sneezing, rhinorhea
Disease type
1nasal airway closure
2.22 ± 0.82house dust
CAP-RAST
 (score) 
2.33 ± 0.89mites
3.22 ± 0.31Japanese cedar
0.44 ± 0.38mugwort
0.56 ± 0.43ragweed
1no
Co-existing ilesses
8yes
5chronic alergic rhinitis
2seasonal alergic conjunctivitis
2alergic conjunctivitis
9no
Alergy prior history
0yes
9noPrior therapy
 (desensitization, surgery) 0yes
drug administrator performed the drug administra-
tion in a way that could not be identified by the physi-
cian nor the clinical study collaborator.
OBSERVED ENDPOINTS
Efficacy
During the 5 minutes after provocation , the nasal
symptoms were observed, including the number of
sneezing attacks and quantity of nasal discharge
(weight of tissues used).
At 5 minutes after provocation, a rhinoscope exami-
nation was conducted to examine and rate the swel-
ling and color of the mucosa of the inferior nasal tur-
binates and nasal discharge . The rating was con-
ducted according to the nasal finding classification of
The Practical Guideline for Management of Allergic
Rhinitis.4 The extent of the inferior nasal turbinate
mucosal swelling and nasal discharge were scored (3
points , 2 points , 1 point , none ; Table 1) , and the
changes in the nasal finding score over time were de-
termined for each drug.10
In addition, nasal airway resistance measurements,
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Fig. 3 Change in the number of sneezing atacks
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Fig. 4 Change in the quantity of nasal discharge (weight of tissues used)
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VTR recording by anterior rhinoscopy for a one-
minute period immediately after provocation and for
a one-minute period beginning at 5 minutes after
provocation , and histamine release rate ( HRT
Shionogi, Osaka, Japan) after first nasal provocation
(30 minutes before drug administration) and at the
end of the last nasal provocation (300 minutes after
drug administration) were also observed.
Safety
At each visit, the physician conducted an examination
at 30 minutes prior to drug administration before the
nasal provocation and at 300 minutes after drug ad-
ministration after the completion of the nasal provoca-
tion.
Patient-reported Evaluation
After completion of all clinical studies, subjects were
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Fig. 5 Change in the inferior nasal turbinate mucosal sweling (nasal find-
ing score)
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surveyed using questionnaires for their impressions
on the efficacy of the study drugs to determine pa-
tients’ opinions.
STUDY METHODS
The nasal provocation was done using Japanese ce-
dar antigen discs containing 50 ng of Cry j1 (kindly
provided by National Hospital Organization Sagami-
hara National Hospital, Kanagawa, Japan), and were
applied to the anterior portion of both inferior nasal
turbinates for 5 minutes. The procedures for each ob-
servation day are indicated below.
Day of Screening Tests (Visit 1)
Subjects were given an explanation regarding their
participation in this clinical study and provided writ-
ten consent.
The subjects underwent a physical examination ,
laboratory tests (hematology, blood chemistry , uri-
nalysis) and the nasal provocation test. The subject’s
background, past medical history and co-existing ill-
nesses, and concomitant drugs were surveyed to con-
Allergology International Vol 55, No3, 2006 www.jsaweb.jp 265
Inhibition of Nasal Provocation by Antihistamine
Fig. 7 The appearance of nasal mucosa by rhinoscope
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firm inclusion criteria and exclusion criteria.
Days of Nasal Provocation Tests (Visits 2, 3, 4;
Fig. 2)
The study drugs were administered at the three vis-
its, and at each visit, a study drug was given as a sin-
gle dose. There was a drug-free period of 14 days be-
tween visits.
The first nasal provocation was conducted at 30
minutes prior to any study drug administration, after
which the study drug was administered. Then, subse-
quent nasal provocation was conducted at 30 minutes,
60 minutes, 180 minutes, and 300 minutes after drug
administration (a total of five times) . At each time
point, the respective observations were conducted.
Statistical Analysis
The results were evaluated as the rate of change in
the value after antigen provocation prior to drug ad-
ministration compared with those after drug admini-
stration, and the value was expressed as a mean ±
standard error. Comparison between study drugs was
performed using the Wilcoxon rank-sum test.
This clinical study was conducted at the Tokyo
Clinical Research Organization for Medicine Clinic
(ToCROM). Prior to conducting the study, the study
was reviewed by the Independent Ethics Committee
of the Osaka Pharmacology Research Clinic and was
approved by the clinic director.
RESULTS
There were nine subjects (5 men, 4 women), mean
age 23.56 ± 0.57 years. The details of subjects’ demo-
graphics are in Table 2. None of the subjects experi-
enced safety problems during the study. One subject
did not return for visits 3 and 4, while one subject did
not return for visit 3. Thus, 7 subjects received all
study drugs.
EFFICACY
Nasal Symptoms
Changes in the number of sneezing attacks and
changes in the quantity of nasal discharge (weight of
tissues used) are shown in Figures 3, 4. The number
of sneezing attacks was maintained below baseline
for up to 300 minutes after administration of epinas-
tine. On the other hand, with fexofenadine and with
placebo, the number of sneezing attacks increased
during the 60 minutes after study drug administra-
tion, followed by a decrease. However, the number of
attacks did not drop below baseline . Epinastine
showed a significant difference against placebo from
30 minutes to 300 minutes after drug administration
and against fexofenadine from 30 minutes to 180 min-
utes after drug administration.
The changes in the quantity of nasal discharge
showed a trend that was similar to that of the number
of sneezing attacks. Epinastine showed values below
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Table 3 Subject impressions
inefectiveneither efective nor inefectiveefective
228.57%242.86%3Epinastine
157.14%428.57%2Fexofenadine
442.86%3 0.00%0Placebo
baseline continuously to 300 minutes after admini-
stration. The changes in the quantity of nasal dis-
charge increased for 30 minutes after administration
of fexofenadine and for 60 minutes after the admini-
stration of placebo, followed by a decrease. Epinas-
tine showed significant differences in the changes in
the quantity of nasal discharge compared with pla-
cebo from 30 minutes to 180 minutes after admini-
stration.
Nasal Findings
Figures 5, 6 show the changes over time in the swel-
ling of the inferior nasal turbinate mucosa and nasal
discharge expressed as the nasal finding score. The
nasal finding score for swelling increased for 60 min-
utes after drug administration for all three study
drugs. There were no significant differences among
the study drugs.
The nasal finding score for the nasal discharge in-
creased for 60 minutes after the administration of
fexofenadine and placebo and was higher than base-
line to 300 minutes after administration, while at no
time point did epinastine show values above baseline.
Epinastine showed significant differences compared
with placebo at 30 minutes after administration and
with fexofenadine at 30 minutes and 60 minutes after
administration.
Nasal Airway Resistance
There were no significant differences among the
study drugs.
VTR Recording By Anterior Rhinoscopy
Figure 7 shows examples of intranasal images at each
measurement time point before and after nasal provo-
cation.
The swelling of the inferior nasal turbinate mucosa
was inhibited from 30 minutes after administration of
epinastine and from 180 minutes after administration
of fexofenadine.
Histamine Release Rates
The mean±standard error at 30 minutes before and
300 minutes after administration were 53.24 ± 15.67%
and 50.16 ± 9.24% for epinastine, 43.00 ± 11.01% and
40.17 ± 10.25% for fexofenadine, and 49.56 ± 14.24%
and 35.44 ± 11.06% for placebo, respectively, showing
decreases with all three study drugs. There were no
significant differences among the study drugs.
SAFETY
None of the subjects experienced any adverse events.
PATIENT-REPORTED EVALUATION
Table 3 shows the subjects’ impressions concerning
the study drugs after the completion of the clinical
study. 3 of 7 subjects given epinastine (42.86%), 2 of 7
subjects given fexofenadine (28.57%) and 0 of 7 sub-
jects given placebo reported that the “study drug was
effective.”
DISCUSSION
The nasal provocation test exposes a fixed amount of
the antigen directly to the nasal mucosa and deter-
mines the changes in the extent of nasal allergy
symptoms. Thus, it is a simple method for objectively
evaluating the efficacy and duration of effect of antial-
lergic agents.7,9,11 Usui et al. have studied the efficacy
of Ketotifen oral agent and nasal agent by the nasal
provocation test using house dust antigens.12 Konno
and Yoshida et al. have also repeated antigen nasal
provocation using the Japanese cedar antigen and
have reported that even during non-dispersion sea-
sons, nasal symptoms seen in the field can be repro-
duced.13,14 When there is no pollen dispersion, the
specific IgE in the nasal mucosa is decreased, but
when antigen in an amount sufficient to elicit the de-
velopment of allergic symptoms is applied, then the
disease becomes apparent . In recent years , many
studies have also been conducted to observe nasal al-
lergy symptoms and conduct drug efficacy evaluation
in pollen (antigen) exposure chambers,6 but from the
standpoint of being able to expose all subjects to a
fixed amount of antigen, the antigen provocation test
is superior for evaluation of nasal symptoms. On the
other hand , in terms of being able to reproduce
symptoms of pollinosis during a pollen-dispersion
season, exposure tests in pollen exposure chambers
are superior to the antigen provocation test. This is
because exposure chambers are closer to the expo-
sure to pollen in the field and can elicit symptoms
that do not arise in antigen provocation tests, such as
symptoms in the eye and throat . However , studies
like the present clinical study involving a small num-
ber of subjects, particularly studies that include de-
tailed assessments such as rhinoscope examination,
require exposure to a fixed amount of antigen. Thus,
we adopted the antigen provocation test. In addition,
repeated provocation reaction was used to reproduce
repeated antigen exposure similar to the repeated ex-
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posure in the field occurring during a pollen-
dispersion season. In a simple one-time antigen expo-
sure, the pollen is in a non-dispersion state and the al-
lergy reaction that occurs is the pure immediate
phase reaction followed by the late phase reaction.7
However, in the actual clinical setting, since there is
repeated exposure to large quantities of dispersed
pollen, it may be important to determine the efficacy
of drugs under conditions with immediate phase and
late phase occurring simultaneously.
It was thought that repeated antigen provocation
reactions can lead to better reproduction of the actual
pollinosis symptoms, and that increasing the number
of exposures may lead to an increase in reactivity .
However, the reaction including nasal mucosal swel-
ling after placebo administration increased to a cer-
tain point after antigen provocation but showed a
trend towards a decrease beyond one hour, and by 5
hours the reactivity was at the level prior to drug ad-
ministration with the first provocation. This may be
because the current clinical study was started in a
pollen-free state. Specific IgE in the nasal mucosa be-
gins to increase at the time of the year when the pol-
len dispersion is starting,15 and it has been shown in
clinical studies in Japanese cedar pollinosis in Japan
that at that time of the year, the hypersensitivity in-
creases gradually.13,14 For this reason, in this clinical
study, the hypersensitivity becomes apparent for a
short period of time, and thereafter, possibly because
of the low level of specific IgE, the decreased reactiv-
ity of mast cells results in decreased production and
release of histamine and decreased nasal discharge
after four or five antigen provocation reactions.
The study drugs used here, epinastine hydrochlo-
ride and fexofenadine hydrochloride , are popular
second-generation antihistamines in Japan. Fexofena-
dine hydrochloride in the pollen-dispersion season
showed clinical efficacy starting around day 2 of ad-
ministration, and improved QOL early in treatment.8
There are no similar data for epinastine hydrochlo-
ride , but a rapid response has been reported in a
clinical study involving the skin. 16 In this study , a
comparison of these two agents and placebo was con-
ducted under conditions close to pollen exposure in
the field using repeated antigen provocations. The re-
sults indicated that epinastine hydrochloride showed
the features characteristic of second-generation anti-
histamines, in which the number of sneezing attacks
and quantity of nasal discharge decreased after anti-
gen provocation at 30 minutes after administration.
The single dose administration inhibited these symp-
toms for at least 3 hours, while the number of sneez-
ing attacks was inhibited for 5 hours. Fexofenadine
hydrochloride also showed a trend towards inhibition
of these symptoms , but the effect was not signifi-
cantly different from placebo. There are actual effi-
cacy data for fexofenadine hydrochloride with respect
to QOL in pollinosis,8 and it is expected that the dif-
ferences would become significant with a larger sam-
ple size, but no significant difference was observed in
this study, possibly because the dose in this clinical
study of once a day differs from the usual dosage
used in clinical practice. The anti-histamine effect was
not caused by only a single dose, but also by one-day
dosage. If we add the second tablets of fexofenadine
hydrochloride , the result of 300 minutes would be
changed. Further work in the future is needed to de-
termine whether significant differences can be seen
using identical experimental methods in a larger
number of subjects. On the other hand, it was evident
that epinastine hydrochloride showed significant dif-
ferences, and thus its rapid efficacy and usefulness
need to be confirmed.
The observation that neither of the drugs showed
significant differences compared with placebo with
respect to efficacy measures such as the inferior na-
sal turbinate mucosal swelling score and nasal airway
resistance may be explained by the fact that this
study involved a single dose administration. The his-
tamine release assay results may also be explained by
this observation.
Based on the results of this clinical study, the effi-
cacy of epinastine hydrochloride in the early phase of
pollinosis treatment was demonstrated by the obser-
vation that a single dose administration led to the
suppression of the nasal mucosal reaction elicited by
repeated provocation. One may consider these data
to be one line of evidence for pollinosis treatment in
the early phase of pollen dispersion or when there is
rapid increase in the quantity of pollen dispersed.
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